Informations pratiques
Adresse

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

Standard

Tel : +33 (0)1 42 11 42 11

Urgences

Gustave Roussy n'assure que les urgences des patients pris en charge à l'Institut.
Urgences uniquement : +33 (0)1 42 11 50 00

GUSTAVE ROUSSY
1er centre de lutte contre le cancer en Europe, 3 000 professionnels mobilisés

Remodelage de la chromatine, réparation de l’ADN et épigénétique

Responsable
Dr Sophie Postel-Vinay
E-mail

 

Frise de présentation (bandeau): 
Remodelage de la chromatine, réparation de l’ADN et épigénétique

Publications majeures

  1. Epigenetic drugs in solid tumours: lessons learned and future promises? Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Nature Reviews Clinical Oncology 2019 Sep 30. doi: 10.1038/s41571-019-0267-4 [Epub ahead of print]
  2. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Chabanon RM, Morel D, Postel-Vinay S. Semin Cancer Biol. 2019 Sep 27. [Epub ahead of print]
  3. ERCC1-deficiency exacerbates tumor cell-intrinsic immunity in response to PARP inhibitors in non-small cell lung cancer. Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Marlow R, Bajrami I, Cardenosa ML, Rouanne M, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt ANJ, Soria JC, Lord JC, Postel-Vinay S. The Journal of Clinical Investigation. 2019 Mar 1;129(3):1211-1228
  4. Understanding genetic determinants of resistance to immune checkpoint blockers. Aspeslagh S, Chabanon RM, Champiat S, Postel-Vinay S. Semin Cancer Biol. 2019 Dec 24. [Epub ahead of print]
  5. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A. Ann Oncol. 2019 May 22; 30 (8), 1401-1403
  6. DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum J, Durand S, Pontoizeau C, Souquère S, Kuo M-S, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S. The Journal of Clinical Investigation 2018 – Apr 2;128(4):1671-1687
  7. Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Aspeslagh S, Morel D, Soria J-C, Postel-Vinay. S. Ann Oncol 2018 Apr 1;29(4):812-824
  8. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Morel D, Almouzni G, Soria JC, Postel-Vinay SAnn. Oncol. 2017 Feb 1;28(2):254-269
  9. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Clin Cancer Res. 2016 Sep 1;22(17):4309-21.
  10. High-throughput screen identifies PARP1/2 inhibitors as novel therapeutic targets for ERCC1-deficient Non-Small Cell Lung Cancer. Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen K, André F, Soria JC, Lord CJ, Ashworth A. – Oncogene.  2013 Nov 21;32(47):5377-87.
Catégorie de la page: